Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel-eluting resorbable scaffold - Lyra Therapeutics

Next Previous
Drug Profile

Paclitaxel-eluting resorbable scaffold - Lyra Therapeutics

Alternative Names: Paclitaxel-eluting stent - Lyra Therapeutics; Stanza DRS; Stanza Drug-eluting Resorbable Scaffold

Latest Information Update: 15 Jan 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 480 Biomedical
  • Developer Lyra Therapeutics
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Peripheral arterial disorders

Most Recent Events

  • 26 Sep 2018 480 Biomedical is now called Lyra Therapeutics
  • 01 Aug 2016 Paclitaxel-eluting resorbable scaffold is still in phase III trials for Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082)
  • 31 Oct 2013 Phase-III clinical trials in Peripheral arterial disorders in Austria, Germany, New Zealand and Switzerland (Intra-arterial) (NCT02097082) (EudraCT2013-002467-26)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top